NAV

Yellow fever vaccine

Identification

Brand Names
Yf-vax
Generic Name
Yellow fever vaccine
DrugBank Accession Number
DB10805
Background

Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of aflavivirusthrough the bite of an infected mosquito. Symptoms of Yellow fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure4. Interestingly, Yellow fever got its name from the characteristic yellowing of the skin and eyes that occurs from the development of jaundice when the virus attacks the liver. Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever. Vaccination with Yellow Fever vaccine is therefore considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 daysLabel. The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease"3.

Yellow Fever is most commonly found in the southern hemisphere, in tropical regions of Africa and Central/South America2. The World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border crossings to prevent international spread of the disease2,5.

Yellow Fever Vaccine is a subcutaneously administered vaccination for the active immunization and prophylaxis of yellow fever in pediatric patients 9 months of age and older. It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infectionLabel,1. The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Flavivirus yellow fever virus 17D-204 whole
  • Yellow fever virus 17D/tiantan live antigen
  • Yellow fever virus live antigen, A
  • Yellow fever virus strain 17D (live, attenuated)
  • Yellow fever virus strain 17D-204 live (attenuated) antigen
  • Yellow fever virus strain 17D-204 live antigen
  • Yellow fever, live attenuated

Pharmacology

Indication

黄热病疫苗是活跃immun表示ization for the prevention of yellow fever in persons 9 months of age and older in the following categories:

  1. Persons Living in or Traveling to Endemic Areas: While the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. Greater risk is associated with living in or traveling to areas of South America and Africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone.

  2. Persons Travelling Internationally Through Countries with Yellow Fever: Some countries require an individual to have a valid International Certificate of Vaccination or Prophylaxis (ICVP) if the individual has been in countries either known or thought to harbor yellow fever virus. The certificate becomes valid 10 days after vaccination with Yellow Fever Vaccine.

  3. Laboratory Personnel: Laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Yellow Fever Vaccine is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infectionLabel. Vaccination with Yellow Fever vaccine is considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 daysLabel.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
这些信息不应该被解释the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abacavir The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Abacavir.
Abatacept The risk or severity of infection can be increased when Yellow fever vaccine is combined with Abatacept.
Acyclovir The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Acyclovir.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Yellow fever vaccine.
Adefovir dipivoxil The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Adefovir dipivoxil.
Aldesleukin The risk or severity of infection can be increased when Yellow fever vaccine is combined with Aldesleukin.
Alefacept The risk or severity of infection can be increased when Yellow fever vaccine is combined with Alefacept.
Alemtuzumab The risk or severity of infection can be increased when Yellow fever vaccine is combined with Alemtuzumab.
Altretamine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Altretamine.
Amantadine The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Amantadine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 地区 Image
Stamaril Injection, powder, lyophilized, for suspension; Kit 1000 [iU]/0.5mL Subcutaneous Sanofi Pasteur Inc. 2016-09-27 Not applicable US flag
Yf-vax Injection, powder, lyophilized, for suspension 4.74 [PFU]/0.5mL Subcutaneous Sanofi Pasteur Inc. 1953-05-22 Not applicable US flag
Yf-vax Powder, for solution 54954 PFU/0.5mL Subcutaneous Sanofi Pasteur Limited 1978-12-31 Not applicable Canada flag
Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End 地区 Image
Stamaril Yellow fever vaccine(1000 [iU]/0.5mL) Injection, powder, lyophilized, for suspension; Kit Subcutaneous Sanofi Pasteur Inc. 2016-09-27 Not applicable US flag

Categories

ATC Codes
J07BL01 — Yellow fever, live attenuated
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
PY4EET359T
CAS number
Not Available

References

General References
  1. Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhaes V, Costa-Pereira C, Albuquerque CP, Muniz LF, Yokoy de Souza T, Oliveira ACV, Martins-Filho OA, da Mota LMH: The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Rev Vaccines. 2018 Jan;17(1):79-90. doi: 10.1080/14760584.2018.1406800. Epub 2017 Nov 27. [Article]
  2. World Health Organization - Yellow Fever Fact Sheet [Link]
  3. World Health Organization - Yellow fever vaccination booster not needed [Link]
  4. CDC - Yellow Fever Symptoms and Treatment [Link]
  5. CDC - Yellow Fever Vaccine [Link]
PubChem Substance
347910911
RxNav
89890
RxList
RxList Drug Page
Drugs.com
Drugs.com药物Page
Wikipedia
Yellow_fever_vaccine
FDA label
Download (246 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Active Not Recruiting Health Services Research Yellow Fever Vaccination Reaction 1
4 Active Not Recruiting Prevention Immunity/Yellow Fever Vaccine 1
4 Completed Prevention Yellow Fever 1
4 Completed Treatment Rotavirus Diarrhea 1
4 Recruiting Basic Science Yellow Fever 2
4 Recruiting Prevention Yellow Fever 1
4 Unknown Status Basic Science Cytotoxicity/Healthy Subjects (HS)/Yellow Fever Vaccination Reaction 1
3 Completed Prevention Dengue Dengue Fever Dengue Hemorrhagic Fever/Dengue Fever/Yellow Fever 1
3 Completed Prevention Disease caused by Salmonella typhi/Japanese Encephalitis/Meningococcal Disease/Meningococcal Meningitis/Rabies/Yellow Fever 1
3 Completed Prevention Human Immunodeficiency Virus (HIV) Infections/Yellow Fever 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Injection, powder, for suspension Intramuscular; Subcutaneous 1000 IU
Injection, powder, lyophilized, for suspension; kit Subcutaneous 1000 [iU]/0.5mL
Injection, powder, for suspension Intramuscular; Subcutaneous
Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous
Injection, powder, for suspension Subcutaneous 1000 IU/0.5ml
Injection Intramuscular; Subcutaneous 1000 IU
Injection, powder, lyophilized, for suspension Subcutaneous 4.74 [PFU]/0.5mL
Powder, for solution Subcutaneous 54954 PFU/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:04 / Updated at April 30, 2023 03:04